



EXPRESS MAIL NO.: EV 913 400 908 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Barbara Ensoli Confirmation No.: 9400
Application No.: 09/555,534 Art Unit: 1648
Filed: May 31, 2000 Examiner: Humphrey, Louise Wang Zhiying
For: HIV TAT, OR DERIVATIVES Attorney Docket No.: 11340-003-999
 THEREOF FOR PROPHYLACTIC
 AND THERAPEUTIC
 VACCINATION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Applicant hereby directs the Examiner's attention to references C190-C196 listed on the accompanying List of References Cited by Applicant. Copies of references C190-C196 are submitted herewith.

Identification of the listed references is not to be construed as an admission of Applicant that such references are available as "prior art" against the subject application.


Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application.

05/04/2007 HGE BREH1 00000002 503013 09555534
01 FC:1806 180.00 DA

Pursuant to 37 C.F.R. § 1.97(c), since this Supplemental Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, but before the mailing date of a final action under 37 C.F.R. § 1.311 or an action that otherwise closes prosecution in this application, it is estimated that a fee of **\$180.00** as set forth in 37 C.F.R. § 1.17(p) is due for this submission. Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Date: May 1, 2007

Respectfully submitted,

 32,605
Adriane M. Antler (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY. DOCKET NO.

11340-003-999

APPLICATION NO.

09/555,534

APPLICANT

Ensoli

FILING DATE

May 31, 2000

GROUP

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A02						
	A03						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	B02						
	B03						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C190	Istituto Superiore di Sanità, "Comunicato Stampa N° 06/05," July 5, 2005.
	C191	Linn S., "Strategies and considerations for protein purifications," Methods Enzymol. 1990;182:9-15.
	C192	McGrath <i>et al.</i> , "Production of crystallizable human chymase from a <i>Bacillus subtilis</i> system," FEBS Lett. 1997 Aug 25;413(3):486-8.
	C193	James <i>et al.</i> , "Purification and biochemical characterization of a vacuolar serine endopeptidase induced by glucose starvation in maize roots," Biochem J. 1996 Nov 15;320 (Pt 1):283-92.
	C194	Goldberg <i>et al.</i> , "Proteases in <i>Escherichia coli</i> ," Methods Enzymol. 1981;80 Pt C:680-702.
	C195	Pirrotta <i>et al.</i> , "General purification schemes for restriction endonucleases," Methods Enzymol. 1980;65(1):89-95.
	C196	Goldstein G., "HIV-1 Tat protein as a potential AIDS vaccine," Nat Med. 1996 Sep;2(9):960-4.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.